Aligos Therapeutics Virtual KOL Event – Phase 2a HERALD Study of ALG-055009 in MASH
About The Event
Join Aligos Therapeutics for a virtual KOL event featuring Stephen Harrison, MD (Visiting Professor, Radcliffe Department of Medicine, University of Oxford), who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH). Dr. Harrison will also discuss the potentially differentiating features of ALG-055009, a next generation thyroid hormone beta agonist, and the Phase 2a HERALD study, which is evaluating the safety and efficacy of ALG-055009.
A live question and answer will follow the formal presentation.